AGIO vs. ARQT

Last updated Apr 2, 2026

Compare and contrast key facts about Agios Pharmaceuticals, Inc. (AGIO) and Arcutis Biotherapeutics, Inc. (ARQT).

Performance

AGIO vs. ARQT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Agios Pharmaceuticals, Inc. (AGIO) and Arcutis Biotherapeutics, Inc. (ARQT). The values are adjusted to include any dividend payments, if applicable.

AGIO vs. ARQT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
AGIO Agios Pharmaceuticals, Inc.	25.61%	-17.16%	47.55%	-20.69%	-14.57%	-24.14%	-11.08%
ARQT Arcutis Biotherapeutics, Inc.	-17.01%	108.47%	331.27%	-78.18%	-28.64%	-26.27%	29.04%

Fundamentals

Market Cap AGIO : $1.99B ARQT : $3.27B
EPS AGIO : -$7.10 ARQT : -$0.12
PS Ratio AGIO : 36.79 ARQT : 8.45
PB Ratio AGIO : 1.67 ARQT : 17.25
Total Revenue (TTM) AGIO : $54.03M ARQT : $376.07M
Gross Profit (TTM) AGIO : $47.68M ARQT : $339.38M
EBITDA (TTM) AGIO : -$438.48M ARQT : -$1.11M

Returns By Period

In the year-to-date period, AGIO achieves a 25.61% return, which is significantly higher than ARQT's -17.01% return.

AGIO

• 1D: 1.06%
• 1M: 17.09%
• YTD: 25.61%
• 6M: -14.67%
• 1Y: 24.78%
• 3Y*: 14.18%
• 5Y*: -8.26%
• 10Y*: -2.00%

ARQT

• 1D: 2.29%
• 1M: -2.67%
• YTD: -17.01%
• 6M: 21.96%
• 1Y: 60.88%
• 3Y*: 29.88%
• 5Y*: -4.12%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

AGIO vs. ARQT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AGIO

AGIO Risk / Return Rank: 54
AGIO Sharpe Ratio Rank: 53
AGIO Sortino Ratio Rank: 53
AGIO Omega Ratio Rank: 66
AGIO Calmar Ratio Rank: 48
AGIO Martin Ratio Rank: 48

ARQT

ARQT Risk / Return Rank: 72
ARQT Sharpe Ratio Rank: 74
ARQT Sortino Ratio Rank: 74
ARQT Omega Ratio Rank: 69
ARQT Calmar Ratio Rank: 72
ARQT Martin Ratio Rank: 72

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AGIO vs. ARQT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Agios Pharmaceuticals, Inc. (AGIO) and Arcutis Biotherapeutics, Inc. (ARQT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	AGIO	ARQT	Difference
Sharpe ratio Return per unit of total volatility	0.35	1.02	-0.67
Sortino ratio Return per unit of downside risk	0.93	1.85	-0.91
Omega ratio Gain probability vs. loss probability	1.20	1.22	-0.02
Calmar ratio Return relative to maximum drawdown	0.33	1.69	-1.36
Martin ratio Return relative to average drawdown	0.70	3.97	-3.27
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

AGIO vs. ARQT - Sharpe Ratio Comparison

The current AGIO Sharpe Ratio is 0.35, which is lower than the ARQT Sharpe Ratio of 1.02. The chart below compares the historical Sharpe Ratios of AGIO and ARQT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	AGIO	ARQT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.35	1.02	-0.67
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.14	-0.06	-0.09
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.03	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.01	0.02	-0.01

Correlation

The correlation between AGIO and ARQT is 0.37, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

AGIO vs. ARQT - Dividend Comparison

Neither AGIO nor ARQT has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

AGIO vs. ARQT - Drawdown Comparison

The maximum AGIO drawdown since its inception was -87.36%, smaller than the maximum ARQT drawdown of -95.02%. Use the drawdown chart below to compare losses from any high point for AGIO and ARQT.

Drawdown Indicators

	AGIO	ARQT	Difference
Max Drawdown Largest peak-to-trough decline	-87.36%	-95.02%	+7.66%
Max Drawdown (1Y) Largest decline over 1 year	-50.89%	-31.99%	-18.90%
Max Drawdown (5Y) Largest decline over 5 years	-72.16%	-94.71%	+22.55%
Max Drawdown (10Y) Largest decline over 10 years	-82.86%	—	—
Current Drawdown Current decline from peak	-74.68%	-34.83%	-39.85%
Average Drawdown Average peak-to-trough decline	-58.57%	-50.46%	-8.11%
Ulcer Index Depth and duration of drawdowns from previous peaks	23.81%	13.63%	+10.18%

Volatility

AGIO vs. ARQT - Volatility Comparison

Agios Pharmaceuticals, Inc. (AGIO) and Arcutis Biotherapeutics, Inc. (ARQT) have volatilities of 15.62% and 15.32%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	AGIO	ARQT	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.62%	15.32%	+0.30%
Volatility (6M) Calculated over the trailing 6-month period	79.68%	43.81%	+35.87%
Volatility (1Y) Calculated over the trailing 1-year period	71.01%	60.16%	+10.85%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	57.37%	71.95%	-14.58%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	57.30%	77.53%	-20.23%

Financials